AZD 8055

Drug Profile

AZD 8055

Alternative Names: AZD8055

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Antineoplastics
  • Mechanism of Action MTORC1 protein inhibitors; MTORC2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 16 Nov 2011 Adverse events, pharmacokinetics & efficacy data from a phase I/II trial in Solid tumours presented at the 23rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
  • 28 Jul 2011 Discontinued - Phase-I for Solid tumours in Japan (PO)
  • 28 Jul 2011 Discontinued - Phase-I/II for Solid tumours in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top